Literature DB >> 31904485

Exosomes in triple negative breast cancer: Garbage disposals or Trojan horses?

Chia Yin Goh1, Cathy Wyse2, Matthew Ho2, Ellen O'Beirne2, Jane Howard3, Sinéad Lindsay3, Pamela Kelly4, Michaela Higgins5, Amanda McCann2.   

Abstract

Triple negative breast cancer (TNBC) is a breast cancer subtype which is particularly aggressive and invasive. The treatment of TNBC has been limited due to the lack of well-defined molecular targets. Exosomes are nano-sized extracellular vesicles that are released from virtually all cell types into the extracellular space. Due to their endocytic origin, exosomes carry valuable information from their cells of origin. Exosomes were first thought to serve as "garbage disposals" that eliminate unwanted cellular components. Later, they were found to be involved in the pathology of many diseases including cancer. Despite their established roles in multiple diseases, only a small number of studies have focused on the role of exosomes in TNBC. In this review, we outline the roles of exosomes in cancer progression, metastasis and drug resistance in this breast cancer subtype. We then further illustrate the potential roles of exosomes as diagnostic tools, therapeutic targets and delivery systems.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31904485     DOI: 10.1016/j.canlet.2019.12.046

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  A comparative analysis of extracellular vesicles (EVs) from human and feline plasma.

Authors:  Jane Howard; Kieran Wynne; Evelin Moldenhauer; Paul Clarke; Ciaran Maguire; Stephanie Bollard; Xiaofei Yin; Lorraine Brennan; Louise Mooney; Stephen Fitzsimons; Melinda Halasz; Ester Rani Aluri; Dermot F Brougham; Walter Kolch; Róisín M Dwyer; Shirley Potter; Pamela Kelly; Amanda McCann
Journal:  Sci Rep       Date:  2022-06-27       Impact factor: 4.996

Review 2.  Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Kyu Sic You; Yong Weon Yi; Jeonghee Cho; Jeong-Soo Park; Yeon-Sun Seong
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

3.  Engineered Cell-Derived Vesicles Displaying Targeting Peptide and Functionalized with Nanocarriers for Therapeutic microRNA Delivery to Triple-Negative Breast Cancer in Mice.

Authors:  Rajendran Jc Bose; Uday Sukumar Kumar; Fernando Garcia-Marques; Yitian Zeng; Frezghi Habte; Jason R McCarthy; Sharon Pitteri; Tarik F Massoud; Ramasamy Paulmurugan
Journal:  Adv Healthc Mater       Date:  2021-12-17       Impact factor: 9.933

Review 4.  Breast Cancer Derived Extracellular Vesicles in Bone Metastasis Induction and Their Clinical Implications as Biomarkers.

Authors:  Simona Taverna; Ilaria Giusti; Sandra D'Ascenzo; Laura Pizzorno; Vincenza Dolo
Journal:  Int J Mol Sci       Date:  2020-05-18       Impact factor: 5.923

Review 5.  Exosomes and breast cancer drug resistance.

Authors:  Xingli Dong; Xupeng Bai; Jie Ni; Hao Zhang; Wei Duan; Peter Graham; Yong Li
Journal:  Cell Death Dis       Date:  2020-11-17       Impact factor: 8.469

Review 6.  Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma.

Authors:  Stefano Burgio; Leila Noori; Antonella Marino Gammazza; Claudia Campanella; Mariantonia Logozzi; Stefano Fais; Fabio Bucchieri; Francesco Cappello; Celeste Caruso Bavisotto
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

7.  Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis.

Authors:  Kai-Jun Hao; Xiao Jia; Wen-Ting Dai; Ze-Min Huo; Hua-Qiang Zhang; Jing-Wei Liu; Xiao-Bing Wang
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 5.738

Review 8.  Applications of Extracellular Vesicles in Triple-Negative Breast Cancer.

Authors:  Frederic St-Denis-Bissonnette; Rachil Khoury; Karan Mediratta; Sara El-Sahli; Lisheng Wang; Jessie R Lavoie
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.